Observational retrospective study of altered biodistribution of tositumomab and 131I-tositumomab

Richard L. Wahl, Thierry J. Horner, Thomas S. Lin, Mark S. Kaminski

Research output: Contribution to journalArticle

Abstract

The tositumomab/131I-tositumomab radioimmunotherapy regimen is administered as a dosimetric dose followed by a therapeutic dose. The biodistribution of the dosimetric dose is assessed by quantitative calculations of whole-body residence time (TBRT) and visual examination of whole-body γ-camera images, to determine the administered radioactivity dose and whether a therapeutic dose can be administered. We investigated whether altered biodistribution of 131I-tositumomab could be identified using quantitative TBRT. Methods: BioClinica, Inc., provided γ-camera images to an independent reviewer to assess altered 131I-tositumomab biodistribution in patients reported to a registry. Results: Of 2,649 therapeutic doses, 5 (0.2%) were cancelled because of altered biodistribution as determined by γ-camera images and TBRT. Of these, 3 γ-camera images were assessed by the independent reviewer; one showed altered biodistribution (0.04%) and was in agreement with the TBRT on-site calculation. Conclusion: TBRT alone should be used to determine altered biodistribution and hence whether to administer the therapeutic dose.

Original languageEnglish (US)
Pages (from-to)1800-1803
Number of pages4
JournalJournal of Nuclear Medicine
Volume56
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Observational Studies
Retrospective Studies
Radioimmunotherapy
Body Image
Therapeutics
Radioactivity
Registries

Keywords

  • Altered biodistribution
  • Therapeutic dose
  • Tositumomab

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Observational retrospective study of altered biodistribution of tositumomab and 131I-tositumomab. / Wahl, Richard L.; Horner, Thierry J.; Lin, Thomas S.; Kaminski, Mark S.

In: Journal of Nuclear Medicine, Vol. 56, No. 11, 01.11.2015, p. 1800-1803.

Research output: Contribution to journalArticle

Wahl, Richard L. ; Horner, Thierry J. ; Lin, Thomas S. ; Kaminski, Mark S. / Observational retrospective study of altered biodistribution of tositumomab and 131I-tositumomab. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 11. pp. 1800-1803.
@article{53815bdaafbd4dc19a238cba1917f645,
title = "Observational retrospective study of altered biodistribution of tositumomab and 131I-tositumomab",
abstract = "The tositumomab/131I-tositumomab radioimmunotherapy regimen is administered as a dosimetric dose followed by a therapeutic dose. The biodistribution of the dosimetric dose is assessed by quantitative calculations of whole-body residence time (TBRT) and visual examination of whole-body γ-camera images, to determine the administered radioactivity dose and whether a therapeutic dose can be administered. We investigated whether altered biodistribution of 131I-tositumomab could be identified using quantitative TBRT. Methods: BioClinica, Inc., provided γ-camera images to an independent reviewer to assess altered 131I-tositumomab biodistribution in patients reported to a registry. Results: Of 2,649 therapeutic doses, 5 (0.2{\%}) were cancelled because of altered biodistribution as determined by γ-camera images and TBRT. Of these, 3 γ-camera images were assessed by the independent reviewer; one showed altered biodistribution (0.04{\%}) and was in agreement with the TBRT on-site calculation. Conclusion: TBRT alone should be used to determine altered biodistribution and hence whether to administer the therapeutic dose.",
keywords = "Altered biodistribution, Therapeutic dose, Tositumomab",
author = "Wahl, {Richard L.} and Horner, {Thierry J.} and Lin, {Thomas S.} and Kaminski, {Mark S.}",
year = "2015",
month = "11",
day = "1",
doi = "10.2967/jnumed.115.156190",
language = "English (US)",
volume = "56",
pages = "1800--1803",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Observational retrospective study of altered biodistribution of tositumomab and 131I-tositumomab

AU - Wahl, Richard L.

AU - Horner, Thierry J.

AU - Lin, Thomas S.

AU - Kaminski, Mark S.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The tositumomab/131I-tositumomab radioimmunotherapy regimen is administered as a dosimetric dose followed by a therapeutic dose. The biodistribution of the dosimetric dose is assessed by quantitative calculations of whole-body residence time (TBRT) and visual examination of whole-body γ-camera images, to determine the administered radioactivity dose and whether a therapeutic dose can be administered. We investigated whether altered biodistribution of 131I-tositumomab could be identified using quantitative TBRT. Methods: BioClinica, Inc., provided γ-camera images to an independent reviewer to assess altered 131I-tositumomab biodistribution in patients reported to a registry. Results: Of 2,649 therapeutic doses, 5 (0.2%) were cancelled because of altered biodistribution as determined by γ-camera images and TBRT. Of these, 3 γ-camera images were assessed by the independent reviewer; one showed altered biodistribution (0.04%) and was in agreement with the TBRT on-site calculation. Conclusion: TBRT alone should be used to determine altered biodistribution and hence whether to administer the therapeutic dose.

AB - The tositumomab/131I-tositumomab radioimmunotherapy regimen is administered as a dosimetric dose followed by a therapeutic dose. The biodistribution of the dosimetric dose is assessed by quantitative calculations of whole-body residence time (TBRT) and visual examination of whole-body γ-camera images, to determine the administered radioactivity dose and whether a therapeutic dose can be administered. We investigated whether altered biodistribution of 131I-tositumomab could be identified using quantitative TBRT. Methods: BioClinica, Inc., provided γ-camera images to an independent reviewer to assess altered 131I-tositumomab biodistribution in patients reported to a registry. Results: Of 2,649 therapeutic doses, 5 (0.2%) were cancelled because of altered biodistribution as determined by γ-camera images and TBRT. Of these, 3 γ-camera images were assessed by the independent reviewer; one showed altered biodistribution (0.04%) and was in agreement with the TBRT on-site calculation. Conclusion: TBRT alone should be used to determine altered biodistribution and hence whether to administer the therapeutic dose.

KW - Altered biodistribution

KW - Therapeutic dose

KW - Tositumomab

UR - http://www.scopus.com/inward/record.url?scp=84946565069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946565069&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.156190

DO - 10.2967/jnumed.115.156190

M3 - Article

VL - 56

SP - 1800

EP - 1803

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -